Antibody-Drug Conjugates (ADCs) Market

Global Market Analysis and Industry Forecast: 2022-2030

Release Date: December 2022 | Number of Pages: 245 | No. of Charts & Figures: 153 | No. of Tables: 84


Antibody-Drug Conjugates (ADCs) combine the targeting ability of antibodies with the killing power of chemotherapy. It mainly comprises a monoclonal antibody (mAb) linked to a highly cytotoxic payload via a synthetic linker. ADCs work by identifying and binding to specific antigens on the surface of tumor cells; upon internalization, the associated cytotoxic payload is released inside the targeted cell, causing microtubule disruption or DNA damage, resulting in apoptosis or cell death.

ADCs have emerged as a novel treatment option for a variety of hematological and solid tumor indications, owing to the various benefits associated with them, such as the ability to selectively kill tumor cells while sparing healthy cells, cost-effectiveness, ease of administration, and high efficacy.

Since the first ADC Mylotarg was approved in 2000, so far 13 ADC products have received market approval, including Adcetris, Kadcyla, Enhertu, and, most recently approved, Elahere (Mirvetuximab Soravtansine).

Currently, 314 ADCs are being evaluated in clinical trials, with 15 late-stage candidates expected to receive market approval during the forecast period.

According to Biotech Forecasts, the global Antibody-Drug Conjugates (ADCs) market was valued at USD 5,270.44 million in 2021 and is estimated to reach USD 33,393.98 million by 2030, registering a CAGR of 18.92% from 2022 to 2030.

The following factors are propelling market expansion: (1) Surging Investment Pertaining to ADCs: ADCs' venture capital landscape is witnessing significant investments. For instance, in December 2021 Emergence Therapeutics raised €87M in Series A, while in May 2022 Tubulis raised €60M in Series B. Furthermore, Synaffix signed a USD 586 million collaboration deal with MacroGenics in February 2022 to build three ADCs.

(2) The Rise in the Prevalence of Cancer: Increasing cancer patient population is the major factor driving the market growth. According to WHO statistics, cancer was responsible for approximately 10 million deaths worldwide in 2020, and it is anticipated to reach 17 million by 2030. 

Other factors that fuel the market growth involve, the surging number of approved products, and rising demand for antibody-based therapies. However, the high costs associated with the process, tumor resistance, and potential side effects might hamper the market growth.

The report also presents a detailed quantitative analysis of the current market trends and future estimations from 2022 to 2030. The forecasts cover 7 Antigen Types, 8 Products, 4 Applications, and 4 Regions.


The report comes with an associated file covering quantitative data from all numeric forecasts presented in the report, as well as a clinical trial data file.


The report has the following key findings:


The report covers the following topics: 



By Antigen Type

By Product

By Application

By Region


Single User License

USD 2,499 

  • Restricted to Only 1 User Access
  • Full PDF Report File
  • N/A
  • N/A
  • N/A

Five User License

USD 2,899

  • Restricted to 5 Users Access
  • Full PDF Report File
  • Free Associated Quantitative Data File
  • N/A
  • N/A

Enterprise License

USD 3,499

  • Unlimited Users Within a Company
  • Full PDF Report File
  • Free Associated Quantitative Data File
  • Clinical Trials Data File
  • Free Data Updates